SOPHiA GENETICS (SOPH) Fundamentals 2026 — Revenue Analysis | SniperIQ
SOPHiA GENETICS (SOPH) is a CH-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of $450M, trading at $6.55 on the NASDAQ. This SniperIQ fundamentals page covers SOPHiA GENETICS's valuation, profitability (net margin -99.7%), revenue ($77M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is SOPHiA GENETICS's market cap?
SOPHiA GENETICS (SOPH) has a market capitalization of approximately $450M, trading at $6.55 on the NASDAQ. Market cap moves with the live share price.
What is SOPHiA GENETICS's P/E ratio?
SOPHiA GENETICS's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 10.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is SOPHiA GENETICS?
SOPHiA GENETICS runs a net profit margin of -99.7%, a gross margin of 67.3%, and an operating margin of -88.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does SOPHiA GENETICS generate?
SOPHiA GENETICS reported revenue of $77M for fiscal year 2025, with net income of -$79M and earnings per share (EPS) of -1.17. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does SOPHiA GENETICS pay a dividend?
SOPHiA GENETICS does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is SOPHiA GENETICS financially healthy?
SOPHiA GENETICS carries a debt-to-equity ratio of 1.37x and a current ratio of 2.06x, with a market beta of 0.96. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is SOPHiA GENETICS a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SOPHiA GENETICS (SOPH) the key facts are: market cap $450M, revenue $77M, 52-week range 2.92-6.77. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track SOPHiA GENETICS's full fundamentals live
Get SOPHiA GENETICS's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.